DOCSLIB.ORG

Useful Pharmacokinetic Equations Symbols Trough (Multiple Dose) K E  Ce0  Cmin  D = Dose 1 Ek E   = Dosing Interval

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Useful Pharmacokinetic Equations Symbols Trough (Multiple Dose) K E  Ce0  Cmin  D = Dose 1 Ek E   = Dosing Interval Useful Pharmacokinetic Equations Symbols Trough (multiple dose) k e Ce0 Cmin D = dose 1 ek e = dosing interval CL = clearance Average concentration (steady state) Vd = volume of distribution D ke = elimination rate constant Cp ss CL ka = absorption rate constant F = fraction absorbed (bioavailability) K0 = infusion rate T = duration of infusion Oral administration C = plasma concentration Plasma concentration (single dose) FDk General a ktea kt C ee Vd kae k Elimination rate constant C Time of maximum concentration (single ln 1 dose) CL C2 lnCC12 ln k e Vd tt tt ka 21 21 ln k e tmax Half-life kkae 0.ln(). 693 Vd 2 0 693 t12/ CL kee k Plasma concentration (multiple dose) kte kta FDka e e C Vd k k 11 e ke e ka Intravenous bolus ae Initial concentration Time of maximum concentration (multiple D dose) C k 0 e Vd kea 1 ln k a kee 1 Plasma concentration (single dose) tmax kte kkae CCe0 Plasma concentration (multiple dose) Average concentration (steady state) FD Ce kte C C 0 CL 1 ek e Clearance Peak (multiple dose) Dose F Cl C0 AUC Cmax 1 ek e Cl ke Vd Equations/Useful_pharmacokinetic_equ_5127 1 Constant rate infusion Calculated peak Cmax Cmax Plasma concentration (during infusion) ekte k * 0 kte with Cmax = measured peak, measured at time C 1 e * CL t after the end of the infusion Plasma concentration (steady state) Calculated trough k CCekte C 0 min min CL * with Cmin = measured trough, measured at Calculated clearance (Chiou equation) time t* before the start of the next infusion 2 k 2 Vd C C CL 0 12 CC CC tt Calculated volume of distribution 12 1221 D 1 eke T Vd Short-term infusion k T ke T e [Cmax (Cmin e )] Peak (single dose) Calculated recommended dosing interval D C 1 ekTe max(1 ) CL T C ln max(desired ) Trough (single dose) Cmin(desired ) T CCekTe min(11 ) max( ) k e Peak (multiple dose) Calculated recommended dose kT D 1 e e 1 eke C max k DCmax(desired ) kVT e CL T 1 e e 1 ekTe Trough (multiple dose) Two-Compartment-Body Model Caett be CCekTe min max AUC a// b Calculated elimination rate constant Vd Vd Vc C area ss ln max C k min Creatinine Clearance e t with C * = measured peak and C * = ()140 age weight max min CL() male measured trough, creat 72 Cp creat measured over the time interval t ()140 age weight CL() female creat 85 Cp creat With weight in kg, age in years, creatinine plasma conc. in mg/dl and CLcreat in ml/min Equations/Useful_pharmacokinetic_equ_5127 2 Ke for aminoglycosides Ke = 0.00293(CrCL) + 0.014 Metabolic and Renal Clearance Clint fub EH = QClfuHbint QCHb lint fu ClH = EQHH = QClfuHbint QH FH = QH Clint fub C in C out Clren = RBFE = GFR C in rate of excretion Clren = plasma concentration Rate of secretion - Rate of reabsorption Clren = fu GFR Plasma concentration Urine flow urine concentration Cl = ren Plasma concentration Ideal Body Weight Volume of Distribution VVP VT K P Male fu V V V IBW = 50 kg + 2.3 kg for each inch over 5ft in P T fuT height Female Clearance IBW = 45.5 kg + 2.3 kg for each inch over 5ft in Dose height Cl AUC Obese ABW = IBW + 0.4*(TBW-IBW) Cl ke Vd Equations/Useful_pharmacokinetic_equ_5127 3 For One Compartment Body Model For a single I.V. bolus administration: For multiple I.V. bolus administration: D nke C D 1 e k t 0 Cn(t) e e V V ke 1 e ket C C e at peak: t = 0; at steady state n If the dosing 0 involves the use at trough: t = of I.V. bolus administration: D 1 Cmax ss k V (1 e e ) ke Cmin ss Cmax ss e For a single short-term I.V. infusion: For multiple short-term I.V. infusion at steady state: Since = t for C max D 1 ekeT D k T If the dosing C 1 e e Cmax max Vk T ke involves the use Vk T e 1 e of I.V. infusion: e ke ( T ) ke ( T ) Cmin Cmax e Cmin Cmax e Last modified 2010 C:\Current Data\pha5127_Dose_Opt_I\equations\5127-28-equations.doc D keT ket Ct e 1 e (most general eq.) during infusion t = T so, VkeT If the dosing D k t e (during infusion) at steady state t , e-ket, t 0 so, involves a I.V. Ct 1 e infusion (more VkeT equations): D k0 k0 D Cpss (steady state) remembering k0 and VkeT Vke CL T CL V ke For a single oral dose: For multiple oral doses: F D ka k t k t ket kat C e e e a F D ka e e V k k C a e V k k ke ka If the dosing a e 1 e 1 e involves oral administration: ka 1 t ln ke max k k k ka 1 e 1 e a e tmax ln ka k k ke 1 e a e Last modified 2010 C:\Current Data\pha5127_Dose_Opt_I\equations\5127-28-equations.doc .
Load more

Recommended publications
  • 1: Clinical Pharmacokinetics 1
    1: CLINICAL PHARMACOKINETICS 1 General overview: clinical pharmacokinetics, 2 Pharmacokinetics, 4 Drug clearance (CL), 6 Volume of distribution (Vd), 8 The half-life (t½), 10 Oral availability (F), 12 Protein binding (PB), 14 pH and pharmacokinetics, 16 1 Clinical pharmacokinetics General overview General overview: clinical pharmacokinetics 1 The ultimate aim of drug therapy is to achieve effi cacy without toxicity. This involves achieving a plasma concentration (Cp) within the ‘therapeutic window’, i.e. above the min- imal effective concentration (MEC), but below the minimal toxic concentration (MTC). Clinical pharmacokinetics is about all the factors that determine variability in the Cp and its time-course. The various factors are dealt with in subsequent chapters. Ideal therapeutics: effi cacy without toxicity Minimum Toxic Concentration (MTC) Ideal dosing Minimum Effective Concentration (MEC) Drug concentration Time The graph shows a continuous IV infusion at steady state, where the dose-rate is exactly appropriate for the patient’s clearance (CL). Inappropriate dosing Dosing too high in relation to the patient’s CL – toxicity likely Minimum Toxic Concentration (MTC) Minimum Effective Concentration (MEC) Dosing too low in relation to the Drug concentration patient’s CL – drug may be ineffective Time Some reasons for variation in CL Low CL High CL Normal variation Normal variation Renal impairment Increased renal blood fl ow Genetic poor metabolism Genetic hypermetabolism Liver impairment Enzyme induction Enzyme inhibition Old age/neonate 2 General overview Clinical Pharmacokinetics Pharmacokinetic factors determining ideal therapeutics If immediate effect is needed, a loading dose (LD) must be given to achieve a desired 1 concentration. The LD is determined by the volume of distribution (Vd).
    [Show full text]
  • Prediction of Clinical Transporter‐Mediated Drug–Drug Interactions
    Citation: CPT Pharmacometrics Syst. Pharmacol. (2020) 9, 211–221; doi:10.1002/psp4.12505 ARTICLE Prediction of Clinical Transporter-Mediated Drug–Drug Interactions via Comeasurement of Pitavastatin and Eltrombopag in Human Hepatocyte Models Simon J. Carter1, Bhavik Chouhan2, Pradeep Sharma3 and Michael J. Chappell1,* A structurally identifiable micro-rate constant mechanistic model was used to describe the interaction between pitavastatin and eltrombopag, with improved goodness-of-fit values through comeasurement of pitavastatin and eltrombopag. Transporter association and dissociation rate constants and passive rates out of the cell were similar between pitavastatin and eltrom- bopag. Translocation into the cell through transporter-mediated uptake was six times greater for pitavastatin, leading to pronounced inhibition of pitavastatin uptake by eltrombopag. The passive rate into the cell was 91 times smaller for pitavas- tatin compared with eltrombopag. A semimechanistic physiologically-based pharmacokinetic (PBPK) model was developed to evaluate the potential for clinical drug–drug interactions (DDIs). The PBPK model predicted a twofold increase in the pita- vastatin peak blood concentration and area under the concentration-time curve in the presence of eltrombopag in simulated healthy volunteers. The use of structural identifiability supporting experimental design combined with robust micro-rate con- stant parameter estimates and a semimechanistic PBPK model gave more informed predictions of transporter-mediated DDIs. Study Highlights WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? model fits through micro-rate constants compared with ✔ Currently, most in vitro models are not guided by macro-rate constants in human hepatocytes, with addi- structural identifiability analysis, relying on substrate-only tional information provided regarding transporter binding.
    [Show full text]
  • Control of Equilibrium Phases (M,T,S) in the Modified Aluminum Alloy
    Materials Transactions, Vol. 44, No. 1 (2003) pp. 181 to 187 #2003 The Japan Institute of Metals EXPRESS REGULAR ARTICLE Control of Equilibrium Phases (M,T,S) in the Modified Aluminum Alloy 7175 for Thick Forging Applications Seong Taek Lim1;*, Il Sang Eun2 and Soo Woo Nam1 1Department of Materials Science and Engineering, Korea Advanced Institute of Science and Technology, 373-1Guseong-dong, Yuseong-gu, Daejeon, 305-701,Korea 2Agency for Defence Development, P.O. Box 35-5, Yuseong-gu, Daejeon, 305-600, Korea Microstructural evolutions, especially for the coarse equilibrium phases, M-, T- and S-phase, are investigated in the modified aluminum alloy 7175 during the primary processing of large ingot for thick forging applications. These phases are evolved depending on the constitutional effect, primarily the change of Zn:Mg ratio, and cooling rate following solutionizing. The formation of the S-phase (Al2CuMg) is effectively inhibited by higher Zn:Mg ratio rather than higher solutionizing temperature. The formation of M-phase (MgZn2) and T-phase (Al2Mg3Zn3)is closely related with both constitution of alloying elements and cooling rate. Slow cooling after homogenization promotes the coarse precipitation of the M- and T-phases, but becomes less effective as the Zn:Mg ratio increases. In any case, the alloy with higher Zn:Mg ratio is basically free of both T and S-phases. The stability of these phases is discussed in terms of ternary and quaternary phase diagrams. In addition, the modified alloy, Al–6Zn–2Mg–1.3%Cu, has greatly reduced quench sensitivity through homogeneous precipitation, which is uniquely applicable in 7175 thick forgings.
    [Show full text]
  • The Excretion and Storage of Ammonia by the Aquatic Larva of Sialis Lutaria (Neuroptera)
    THE EXCRETION AND STORAGE OF AMMONIA BY THE AQUATIC LARVA OF SIALIS LUTARIA (NEUROPTERA) BY B. W. STADDON* Department of Zoology, University of Durham, King's College, Newcastle upon Tyne (Received 12 April 1954) INTRODUCTION Delaunay (1931), in a review of the invertebrates, showed that an excellent correla- tion existed between the nature of the major nitrogenous component of the excreta and the nature of the environment, aquatic or terrestrial, in which an animal lived. Ammonia was shown to predominate in the excreta of aquatic species, urea or uric acid in the excreta of semi-terrestrial or terrestrial species. Delaunay put forward the view that the synthesis by these terrestrial forms of more complex molecules from ammonia was essentially a detoxication mechanism necessitated by a restricted water supply. Although the insects are primarily a terrestrial group, representatives of a number of orders have become aquatic in one or more stages of their life histories. It is well known that those terrestrial species which have been examined, with the notable exception of blowfly larvae, excrete the bulk of their nitrogen in the form of uric acid (Wigglesworth, 1950). The possibility, however, that aquatic species might have reverted to ammonotelism does not seem to have been examined. Preliminary tests were carried out on the excreta of a variety of aquatic insects. In all cases ammonia was found to be the major nitrogenous excretory product. An investigation into various aspects of the metabolism, toxicity and excretion of ammonia was then undertaken on the aquatic larva of Siatis lutaria. It is the purpose of the present communication to present some observations on the excretion and storage of ammonia in this species.
    [Show full text]
  • 214 CHAPTER 5 [T, D]-DELETION in ENGLISH in English, a Coronal Stop
    CHAPTER 5 [t, d]-DELETION IN ENGLISH In English, a coronal stop that appears as last member of a word-final consonant cluster is subject to variable deletion – i.e. a word such as west can be pronounced as either [wEst] or [wEs]. Over the past thirty five years, this phenomenon has been studied in more detail than probably any other variable phonological phenomenon. Final [t, d]-deletion has been studied in dialects as diverse as the following: African American English (AAE) in New York City (Labov et al., 1968), in Detroit (Wolfram, 1969), and in Washington (Fasold, 1972), Standard American English in New York and Philadelphia (Guy, 1980), Chicano English in Los Angeles (Santa Ana, 1991), Tejano English in San Antonio (Bayley, 1995), Jamaican English in Kingston (Patrick, 1991) and Trinidadian English (Kang, 1 1994), etc.TP PT Two aspects that stand out from all these studies are (i) that this process is strongly grammatically conditioned, and (ii) that the grammatical factors that condition this process are the same from dialect to dialect. Because of these two facts [t, d]-deletion is particularly suited to a grammatical analysis. In this chapter I provide an analysis for this phenomenon within the rank-ordering model of EVAL. The factors that influence the likelihood of application of [t, d]-deletion can be classified into three broad categories: the following context (is the [t, d] followed by a consonant, vowel or pause), the preceding context (the phonological features of the consonant preceding the [t, d]), the grammatical status of the [t, d] (is it part of the root or 1 TP PT This phenomenon has also been studied in Dutch – see Schouten (1982, 1984) and Hinskens (1992, 1996).
    [Show full text]
  • Tail Risk Premia and Return Predictability∗
    Tail Risk Premia and Return Predictability∗ Tim Bollerslev,y Viktor Todorov,z and Lai Xu x First Version: May 9, 2014 This Version: February 18, 2015 Abstract The variance risk premium, defined as the difference between the actual and risk- neutral expectations of the forward aggregate market variation, helps predict future market returns. Relying on new essentially model-free estimation procedure, we show that much of this predictability may be attributed to time variation in the part of the variance risk premium associated with the special compensation demanded by investors for bearing jump tail risk, consistent with idea that market fears play an important role in understanding the return predictability. Keywords: Variance risk premium; time-varying jump tails; market sentiment and fears; return predictability. JEL classification: C13, C14, G10, G12. ∗The research was supported by a grant from the NSF to the NBER, and CREATES funded by the Danish National Research Foundation (Bollerslev). We are grateful to an anonymous referee for her/his very useful comments. We would also like to thank Caio Almeida, Reinhard Ellwanger and seminar participants at NYU Stern, the 2013 SETA Meetings in Seoul, South Korea, the 2013 Workshop on Financial Econometrics in Natal, Brazil, and the 2014 SCOR/IDEI conference on Extreme Events and Uncertainty in Insurance and Finance in Paris, France for their helpful comments and suggestions. yDepartment of Economics, Duke University, Durham, NC 27708, and NBER and CREATES; e-mail: [email protected]. zDepartment of Finance, Kellogg School of Management, Northwestern University, Evanston, IL 60208; e-mail: [email protected]. xDepartment of Finance, Whitman School of Management, Syracuse University, Syracuse, NY 13244- 2450; e-mail: [email protected].
    [Show full text]
  • Clinical Pharmacology 1: Phase 1 Studies and Early Drug Development
    Clinical Pharmacology 1: Phase 1 Studies and Early Drug Development Gerlie Gieser, Ph.D. Office of Clinical Pharmacology, Div. IV Objectives • Outline the Phase 1 studies conducted to characterize the Clinical Pharmacology of a drug; describe important design elements of and the information gained from these studies. • List the Clinical Pharmacology characteristics of an Ideal Drug • Describe how the Clinical Pharmacology information from Phase 1 can help design Phase 2/3 trials • Discuss the timing of Clinical Pharmacology studies during drug development, and provide examples of how the information generated could impact the overall clinical development plan and product labeling. Phase 1 of Drug Development CLINICAL DEVELOPMENT RESEARCH PRE POST AND CLINICAL APPROVAL 1 DISCOVERY DEVELOPMENT 2 3 PHASE e e e s s s a a a h h h P P P Clinical Pharmacology Studies Initial IND (first in human) NDA/BLA SUBMISSION Phase 1 – studies designed mainly to investigate the safety/tolerability (if possible, identify MTD), pharmacokinetics and pharmacodynamics of an investigational drug in humans Clinical Pharmacology • Study of the Pharmacokinetics (PK) and Pharmacodynamics (PD) of the drug in humans – PK: what the body does to the drug (Absorption, Distribution, Metabolism, Excretion) – PD: what the drug does to the body • PK and PD profiles of the drug are influenced by physicochemical properties of the drug, product/formulation, administration route, patient’s intrinsic and extrinsic factors (e.g., organ dysfunction, diseases, concomitant medications,
    [Show full text]
  • In Vitro Interactions of Epacadostat and Its Major Metabolites With
    DMD Fast Forward. Published on March 10, 2017 as DOI: 10.1124/dmd.116.074609 This article has not been copyedited and formatted. The final version may differ from this version. DMD # 74609 In vitro interactions of epacadostat and its major metabolites with human efflux and uptake transporters: Implications for pharmacokinetics and drug interactions Qiang Zhang, Yan Zhang, Jason Boer, Jack G. Shi, Peidi Hu, Sharon Diamond, and Downloaded from Swamy Yeleswaram Incyte Corporation, Wilmington, DE 19803 dmd.aspetjournals.org at ASPET Journals on September 29, 2021 1 DMD Fast Forward. Published on March 10, 2017 as DOI: 10.1124/dmd.116.074609 This article has not been copyedited and formatted. The final version may differ from this version. DMD # 74609 Running title: Interactions of Epacadostat with Transporters Corresponding Author: Qiang Zhang, Ph.D. Incyte Corporation 1801 Augustine Cut-Off Wilmington, DE 19803 Downloaded from Email: [email protected] Phone: 302-498-5827 Fax: 302-425-2759 dmd.aspetjournals.org Number of Text Pages: 24 Number of Figures: 8 at ASPET Journals on September 29, 2021 Number of Tables: 6 Number of References: 24 The number of words of Abstract: 247 The number of words of Introduction: 655 The number of words of Discussion: 1487 Non-standard Abbreviations: EPAC, epacadostat; IDO1, indoleamine 2,3-dioxygenase 1; EHC, enterohepatic circulation; NME, new chemical entity; TEER, transepithelial electrical resistance; HBSS, Hank's Balanced Salt Solution; KO, knockout; CSA, cyclosporin A; IC50, half-maximal inhibitory concentration; ER, efflux ratio 2 DMD Fast Forward. Published on March 10, 2017 as DOI: 10.1124/dmd.116.074609 This article has not been copyedited and formatted.
    [Show full text]
  • Tail of a Linear Diffusion with Markov Switching
    The Annals of Applied Probability 2005, Vol. 15, No. 1B, 992–1018 DOI: 10.1214/105051604000000828 c Institute of Mathematical Statistics, 2005 TAIL OF A LINEAR DIFFUSION WITH MARKOV SWITCHING By Benoˆıte de Saporta and Jian-Feng Yao Universit´ede Rennes 1 Let Y be an Ornstein–Uhlenbeck diffusion governed by a sta- tionary and ergodic Markov jump process X: dYt = a(Xt)Yt dt + σ(Xt) dWt, Y0 = y0. Ergodicity conditions for Y have been obtained. Here we investigate the tail propriety of the stationary distribution of this model. A characterization of either heavy or light tail case is established. The method is based on a renewal theorem for systems of equations with distributions on R. 1. Introduction. The discrete-time models Y = (Yn,n ∈ N) governed by a switching process X = (Xn,n ∈ N) fit well to the situations where an autonomous process X is responsible for the dynamic (or regime) of Y . These models are parsimonious with regard to the number of parameters, and extend significantly the case of a single regime. Among them, the so- called Markov-switching ARMA models are popular in several application fields, for example, in econometric modeling [see Hamilton (1989, 1990)]. More recently, continuous-time versions of Markov-switching models have been proposed in Basak, Bisi and Ghosh (1996) and Guyon, Iovleff and Yao (2004), where ergodicity conditions are established. In this paper we investi- gate the tail property of the stationary distribution of this continuous-time process. One of the main results (Theorem 2) states that this model can provide heavy tails, which is one of the major features required in nonlinear time-series modeling.
    [Show full text]
  • 624.Full.Pdf
    1521-009X/44/5/624–633$25.00 http://dx.doi.org/10.1124/dmd.115.068932 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 44:624–633, May 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Development of a Rat Plasma and Brain Extracellular Fluid Pharmacokinetic Model for Bupropion and Hydroxybupropion Based on Microdialysis Sampling, and Application to Predict Human Brain Concentrations Thomas I.F.H. Cremers, Gunnar Flik, Joost H.A. Folgering, Hans Rollema, and Robert E. Stratford, Jr. Brains On-Line BV, Groningen, The Netherlands (T.I.F.H.C., G.F. J.H.A.F.); Rollema Biomedical Consulting, Mystic, Connecticut (H.R.); and Division of Pharmaceutical Sciences, Mylan School of Pharmacy, Duquesne University, Pittsburgh, Pennsylvania (R.E.S.) Received December 11, 2015; accepted February 24, 2016 Downloaded from ABSTRACT Administration of bupropion [(6)-2-(tert-butylamino)-1-(3-chlorophenyl) concentration ratio at early time points was observed with propan-1-one] and its preformed active metabolite, hydroxybupropion bupropion; this was modeled as a time-dependent uptake clear- [(6)-1-(3-chlorophenyl)-2-[(1-hydroxy-2-methyl-2-propanyl)amino]- ance of the drug across the blood–brain barrier. Translation of the 1-propanone], to rats with measurement of unbound concentrations model was used to predict bupropion and hydroxybupropion dmd.aspetjournals.org by quantitative microdialysis sampling of plasma and brain extra- exposure in human brain extracellular fluid after twice-daily cellular fluid was used to develop a compartmental pharmacoki- administration of 150 mg bupropion. Predicted concentrations netics model to describe the blood–brain barrier transport of both indicate that preferential inhibition of the dopamine and norepi- substances.
    [Show full text]
  • Microrna Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms Behind Variable Drug Disposition and Strategy to Develop More Effective Therapy
    1521-009X/44/3/308–319$25.00 http://dx.doi.org/10.1124/dmd.115.067470 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 44:308–319, March 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Minireview MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy Ai-Ming Yu, Ye Tian, Mei-Juan Tu, Pui Yan Ho, and Joseph L. Jilek Department of Biochemistry & Molecular Medicine, University of California Davis School of Medicine, Sacramento, California Received September 30, 2015; accepted November 12, 2015 Downloaded from ABSTRACT Knowledge of drug absorption, distribution, metabolism, and excre- we review the advances in miRNA pharmacoepigenetics including tion (ADME) or pharmacokinetics properties is essential for drug the mechanistic actions of miRNAs in the modulation of Phase I and development and safe use of medicine. Varied or altered ADME may II drug-metabolizing enzymes, efflux and uptake transporters, and lead to a loss of efficacy or adverse drug effects. Understanding the xenobiotic receptors or transcription factors after briefly introducing causes of variations in drug disposition and response has proven the characteristics of miRNA-mediated posttranscriptional gene dmd.aspetjournals.org critical for the practice of personalized or precision medicine. The regulation. Consequently, miRNAs may have significant influence rise of noncoding microRNA (miRNA) pharmacoepigenetics and on drug disposition and response. Therefore, research on miRNA pharmacoepigenomics has come with accumulating evidence sup- pharmacoepigenetics shall not only improve mechanistic under- porting the role of miRNAs in the modulation of ADME gene standing of variations in pharmacotherapy but also provide novel expression and then drug disposition and response.
    [Show full text]
  • A Primer on Pharmacology
    A primer on pharmacology Universidade do Algarve Faro 2017 by Ferdi Engels, Ph.D. 1 2 1 3 Utrecht university campus ‘de Uithof’ Dept. of Pharmaceutical Sciences Division of Pharmacology 4 2 Bachelor and master education Ferdi Engels, PhD ‐ Associate professor of pharmacology ‐ Director of Undergraduate School of Science PhD training Research expertise 5 for today 1. Understand the main concepts of pharmacokinetics Main concept 2. Be able to apply this new knowledge 6 3 Pharmacology is about drugs………. Drugs = chemicals that alter physiological processes in the body for treatment, prevention, or cure of diseases input output (administration of the drug) (biological response) ‐ dose ‐ no effect ‐ frequency of administration ‐ beneficial effects ‐ route of administration ‐ adverse / toxic effects onset, intensity, and duration of therapeutic effects 7 Pharmacology is about drugs………. Drugs = chemicals that alter physiological processes in the body for treatment, prevention, or cure of diseases What does the body do to the drug? pharmacokinetics What does the drug do to the body? pharmacodynamics 8 4 Thursday, June 15 Lecture on topic 1 Workshop on topic 1 Friday, June 16 Lecture on topic 2 Workshop on topic 2 Course Topic 1 Course Topic 2 9 Rosenbaum ‐ Basic pharmacokinetics and pharmacodynamics: an integrated textbook and computer simulations, 1st ed. (2011) input output (administration of the drug) (biological response) ‐ dose ‐ no effect ‐ frequency of administration ‐ beneficial effects ‐ route of administration ‐ adverse / toxic effects
    [Show full text]